We're continuously improving your experience and this page will be retired soon. If you rely on the content on this page, check out Screeners Beta for similar content and functionality.
23.85k followers • 13 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Watchlist | Change Today | 1 Month Return | 1 Year Return | Total Return |
---|---|---|---|---|
The Fight Against COVID19 | +1.95% | - | - | - |
^GSPC | +0.64% | +1.77% | +30.69% | +6303.15% |
Symbol | Company Name | Last Price | Change | % Change | Market Time | Volume | Avg Vol (3 month) | Market Cap |
---|---|---|---|---|---|---|---|---|
JNJ | Johnson & Johnson | 155.445 | +2.34 | +1.53% | 1:42 PM EST | 3.94M | 6.34M | 374.25B |
ABBV | AbbVie Inc. | 172.12 | +4.36 | +2.60% | 1:42 PM EST | 3.32M | 5.44M | 304.16B |
PFE | Pfizer Inc. | 25.06 | +0.12 | +0.48% | 1:42 PM EST | 22.41M | 36.46M | 142.01B |
SNY | Sanofi | 47.971 | +0.19 | +0.40% | 1:42 PM EST | 663.52k | 1.88M | 121.62B |
GILD | Gilead Sciences, Inc. | 89.545 | +0.92 | +1.03% | 1:42 PM EST | 1.64M | 6.73M | 111.60B |
REGN | Regeneron Pharmaceuticals, Inc. | 752.2 | +8.85 | +1.19% | 1:42 PM EST | 347.27k | 693.24k | 82.66B |
GSK | GSK plc | 33.595 | +0.25 | +0.73% | 1:42 PM EST | 4.36M | 5.64M | 68.54B |
TAK | Takeda Pharmaceutical Company Limited | 13.265 | -0.02 | -0.19% | 1:42 PM EST | 1.91M | 1.72M | 42.76B |
BNTX | BioNTech SE | 106.4775 | +4.34 | +4.25% | 1:41 PM EST | 451.32k | 1.08M | 25.53B |
MRNA | Moderna, Inc. | 38.19 | +1.25 | +3.38% | 1:42 PM EST | 5.28M | 6.49M | 14.70B |
NVAX | Novavax, Inc. | 8.21 | +0.15 | +1.86% | 1:42 PM EST | 1.79M | 6.37M | 1.32B |
VIR | Vir Biotechnology, Inc. | 6.8599 | +0.12 | +1.78% | 1:42 PM EST | 1.33M | 995.56k | 944.75M |
INO | Inovio Pharmaceuticals, Inc. | 4.145 | +0.17 | +4.41% | 1:40 PM EST | 351.83k | 320.30k | 108.18M |
Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds in the form of emerging infectious diseases, I’m concerned that the company may never deliver on its pipeline potential. One reason for this is the company’s extraordinary cash burn, and another is that these formative loss-making years may be negatively impacted by changing federal policy with a vaccine skeptic taking to the Department of Health and Human Services. As much
PFE vs. NVO: Which Stock Is the Better Value Option?
Investor confidence in certain major companies has propelled markets higher, but there are also those betting against big-name stocks through short selling.